The Hyderabad-based pharmaceutical major reported a consolidated revenue from operations of Rs 2,410 crore for the first quarter of FY26, up 13.8% from Rs 2,118 crore in the same period last year.
The company said its total income for the June 2025 quarter stood at Rs 2,529 crore, compared with Rs 2,197 crore in Q1 FY25.
Profit before tax (PBT) for the reporting period rose to Rs 733 crore, up from Rs 604 crore in the year-ago quarter, though it was lower than the Rs 864 crore reported in the March 2025 quarter.
The company also reported a forex gain of Rs 39 crore, reversing a Rs 1 crore loss in the same period last year.
Stock moves and technicals
At 12:13 PM IST, shares of Divi’s Laboratories were trading 2.9% lower at Rs 6,225.30 on the BSE following the earnings announcement.The stock has gained 2.7% so far in 2025 but is down nearly 10% over the past month.From a technical standpoint, the stock is currently trading below six of its eight key simple moving averages (SMA), including the 5-day, 10-day, 20-day, 30-day, 50-day and 100-day SMAs, while the stock is trading above its 150-day and 200-day SMAs, indicating bullish undertones in the long-term charts.
The Relative Strength Index (RSI) stands at 37.1. RSI below 30 is considered oversold, and above 70 is overbought. Meanwhile, the Moving Average Convergence Divergence (MACD) is at -62.1 and remains below the center and signal lines, reinforcing a strong bearish indicator.
Also read | Swiggy vs Eternal: Which stock promises better value delivery post Q1 show?
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)